Table 1.
Clinical, MR-guided biopsy, and MRI parameters at baseline
| All patients | RPE subcohort | |
|---|---|---|
| Patients (n) | 145 | 82 |
| Age in years; median (IQR) | 71 (65–76) | 68 (65–73) |
| PSA in ng/ml; median (IQR) | 10.9 (6.8–19.1) | 9.6 (6.5–17.8) |
| PSAD median (IQR) | 0.25 (0.16–0.42) | 0.23 (0.14–0.39) |
| ISUP GG after MR-guided biopsy(n) | ||
| 1 | 1* | 1* |
| 2 | 4* | 4* |
| 3 | 4* | 4* |
| 4 | 82 | 41 |
| 5 | 55 | 32 |
| Percentage of infiltration in biopsy core median (IQR) | 70 (50–85) | 65 (50–80) |
| PI-RADS v2.1 (n) | ||
| 3 | 2 | 2 |
| 4 | 43 | 22 |
| 5 | 100 | 58 |
| T2 | ||
| IL localization | ||
| PZ | 112 | 67 |
| TZ | 33 | 15 |
| IL diameter in mm; median (IQR) | 15 (12–22) | 17 (12–22) |
| Contact length to pseudocapsule (LCC) in mm; median (IQR) | 17 (12–26) | 18 (12–26) |
| MRI T3 stage in % | 48 | 51 |
| DWI | ||
| ADC value of IL in ×10−6 mm2/s. median (IQR) | 668 (571–798) | 662 (544–785) |
| DCE | ||
| IL with focal enhancement on DCE in % | 94 | 96 |
MRI magnetic resonance imaging, PSA prostate specific antigen, PSAD prostate specific antigen density, TZ transition zone, PZ peripheral zone, DWI diffusion weighted imaging, ADC apparent diffusion coefficient, DCE dynamic contrast enhancement, IQR interquartile range, IL index lesion; T stage Tumor stage, ISUP International Society of Urological Pathology, GG grade group, RPE radical prostatectomy
*ISUP GG 4 or 5 in RPE